Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

CVS Says Covid-19 Vaccinations Slow -- 2nd Update

05/04/2021 | 08:11am EDT

By Sharon Terlep

CVS Health Corp. said demand for Covid-19 vaccinations has fallen by about 30% recently as Americans' hesitancy to receive the shots outweighs expanding eligibility and access.

The pharmacy chain has administered more than 17 million shots, which are now available at more than 8,300 U.S. locations. Like rivals, CVS has begun offering same-day appointments for injections in a bid to improve uptake.

In the early months of the U.S. vaccine rollout, restrictions on who could receive a vaccine and short supply of doses prevented many people from getting shots. Now, many parts of the country are reporting excess doses and unfilled appointments even as less than 60% of American adults have received at least one dose.

Anyone 16 or older is eligible for a vaccine in the U.S., a change from the months in which only certain groups of people could get a shot.

Pfizer Inc. and BioNTech SE last month asked U.S. health regulators to allow their Covid-19 vaccine to be given to adolescents to extend their shot's use to children 12 years and older.

On Tuesday, Pfizer reported a surge in first-quarter revenue and said it expects the vaccine to generate $26 billion in sales this year. It had previously forecast $15 billion in sales from the vaccine.

CVS Health said Tuesday it now expects Covid-19 vaccines to contribute about 2% to the company's prescription volume growth this year, on the low end of initial projections of 2% to 3%.

CVS Health Chief Executive Karen Lynch said Covid-19 vaccinations and testing are bolstering the company's business, helping make up for a weak flu and cold season. On a conference call, Ms. Lynch said that in April "vaccinated customers are more actively shopping in CVS locations." For customers new to the company through Covid-19 testing, she said the company is seeing around 9% filling a new prescription at a CVS pharmacy.

The company said revenue in the segment that fulfills medication prescriptions and sells general products rose 2.3% to $23.27 billion in the first quarter, driven by higher Covid-19 testing and vaccinations. Partly offsetting the gains was lower front-store revenue.

The company posted first-quarter revenue of $69.1 billion, up 3.5%. Same-store sales, or those at retail pharmacy stores that had been operating for more than one year, rose 0.4%.

CVS, along with rival Walgreens Boots Alliance Inc., supermarket chain Kroger Co. and Walmart Inc. have been pushing to get consumers to visit their locations to receive vaccines. The daily number of new Covid-19 cases have been declining and governors across the U.S. are now rolling back restrictions implemented during the pandemic.

Net income totaled $2.22 billion for the first quarter at CVS, up from $2 billion in the same period last year. Adjusted earnings were $2.04 a share, ahead of Wall Street estimates.

Anna Wilde Matthews and Dave Sebastian contributed to this article.

Write to Sharon Terlep at sharon.terlep@wsj.com

(END) Dow Jones Newswires

05-04-21 1011ET

Stocks mentioned in the article
ChangeLast1st jan.
BIONTECH SE 9.35% 183.71 Delayed Quote.125.36%
CVS HEALTH CORPORATION 1.68% 85.11 Delayed Quote.24.61%
PFIZER, INC. 1.00% 39.58 Delayed Quote.6.47%
05/07BILL GATES : Stocks That Defined the Week
05/06Walmart Health To Acquire Telehealth Provider MeMD -- 4th Update
05/06INSIDER TRENDS : CVS Health Insider Exercises Options Extending 90-Day Buying Tr..
05/06INSIDER TRENDS : Insider Adds to Selling Trend at CVS Health
05/06Walmart Health To Acquire Telehealth Provider MeMD -- 3rd Update
05/06CVS HEALTH  : Credit Suisse Adjusts Price Target on CVS Health to $100 From $91,..
05/06WALL STREET STOCK EXCHANGE : How will inflation impact recovery?
05/06CVS HEALTH  : to Administer No-Cost COVID-19 Vaccines at 19 Select CVS Pharmacy ..
05/06CVS HEALTH  : DA Davidson Adjusts CVS Health's Price Target to $95 From $84, Cit..
05/06TODAY'S ANALYST RECOMMENDATIONS : Lowe, National Grid, Pearson, Thomson Reuters,..
More news
Financials (USD)
Sales 2021 282 B - -
Net income 2021 8 214 M - -
Net Debt 2021 50 189 M - -
P/E ratio 2021 13,5x
Yield 2021 2,35%
Capitalization 112 B 112 B -
EV / Sales 2021 0,58x
EV / Sales 2022 0,53x
Nbr of Employees 256 500
Free-Float 75,2%
Duration : Period :
CVS Health Corporation Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CVS HEALTH CORPORATION
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus BUY
Number of Analysts 28
Average target price 92,73 $
Last Close Price 85,11 $
Spread / Highest target 25,7%
Spread / Average Target 8,95%
Spread / Lowest Target -4,83%
EPS Revisions
Managers and Directors
Karen S. Lynch President, Chief Executive Officer & Director
Eva C. Boratto Chief Financial Officer & Executive Vice President
David Wyatt Dorman Chairman
Troyen A. Brennan Chief Medical Officer & Executive Vice President
Jonathan C. Roberts Chief Operating Officer & Executive Vice President
Sector and Competitors